Lupin launches generic Niaspan tablets in US market

Mumbai-based pharma major Lupin Ltd today launched its generic version of Niaspan extended release tablets, used in reducing cholesterol in the US market.

The company's US subsidiary, Lupin Pharmaceuticals Inc has launched the generic Niaspan tablets in multiple strengths of 500mg, 750 mg & 1000 mg having received final approval from the US Food and Drug Administration (USFDA), Lupin said in a statement.

These tablets are generic equivalent of AbbVie Inc's Niaspan tablets.

Commenting on the launch, Lupin Ltd Managing Director Nilesh Gupta said: "We are happy to launch this product having received approval from the (US) FDA yesterday. The launch bears testimony to our commitment to serving our customers and patients by bringing high quality, affordable medicines to the market."

Citing IMS MAT data, the company said Niaspan Tablets had annual sales of of approximately USD 1 billion in the US in 2013.

Niaspan tablets are used with diet to lower bad cholesterol while increasing the levels of good cholesterol in the body.

Lupin Ltd shares gained 0.45 per cent on the BSE from the previous close, ending the day at Rs 944.2 per scrip.

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

EDITORIAL OF THE DAY

  • India’s festivals teach us to share our wealth and joy

    India is an aporia in its own true sense.

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

Chander Mohan Sethi

CMD, Reckitt Benckiser India

COLUMNIST

Tushar Gandhi

Sustainable model for rural sanitation

Prime minister Narendra Modi has promised to build a toilet ...

Zehra Naqvi

How smells evoke strong memories

Remember that time when a passing fragrance transported you to ...

Dharmendra Khandal

Indian zoos need a fresh approach

Recently, when a man jumped in a tiger trench of ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture